血流储备分数指导急性心肌梗死合并多支血管病变治疗的成本效益:FRAME-AMI随机临床试验预设分析
本文为FRAME-AMI随机临床试验的预设成本效益分析,纳入562例急性心肌梗死合并多支血管病变患者,随机接受FFR指导或造影指导的非IRA病变PCI。采用Markov模型模拟死亡、心肌梗死和再次血运重建,结果显示FFR指导组QALYs增加0.06,人均累积总费用减少1208美元,ICER为-19484美元,INB为3378美元。概率敏感性分析显示FFR指导具有成本效益的迭代可能性为97%。作者认为对这类患者应考虑FFR指导的非IRA狭窄治疗策略。
要点
- FRAME-AMI试验随机562例急性心肌梗死合并多支血管病变患者,平均年龄63.3(11.4)岁,男性474例(84.3%)。
- FFR指导PCI较造影指导QALYs增加0.06,人均累积总费用减少1208美元。
- ICER为-19484美元,INB为3378美元,概率敏感性分析显示FFR指导具有成本效益的迭代可能性为97%。
- 使用FLOWER-MI和FRAME-AMI试验配对Meta分析的转移概率时,FFR指导在韩国、美国、欧洲医疗体系均更具成本效益,INB分别为3910、8557、2210美元。
- 概率敏感性分析中FFR指导具有成本效益的迭代可能性在韩国、美国、欧洲分别为85%、82%、31%。
适用人群与场景
- 年龄19岁及以上,患有ST段抬高型心肌梗死(STEMI)或非STEMI,并成功接受直接或紧急PCI,且至少存在1处非IRA病变(主要心外膜冠状动脉或主要分支血管直径≥2.0 mm、直径狭窄>50%)的患者。
诊断标准与关键阈值
- 非IRA病变定义为主要心外膜冠状动脉或主要分支血管直径≥2.0 mm、直径狭窄>50%。
处置流程与药物剂量
- 对非IRA病变行FFR指导与造影指导的PCI进行比较;FFR指导组根据FFR结果决定是否行PCI。
研究设计与关键结果
- FRAME-AMI随机临床试验的预设成本效益分析,纳入562例患者,随机分配至FFR指导或造影指导的非IRA病变PCI,随机化时间为2016年8月19日至2020年12月24日,数据分析于2023年8月27日进行。
- 采用Markov状态转移模型模拟死亡、心肌梗死和再次血运重建,未来医疗成本和效益按每年4.5%贴现,使用韩国、美国、欧洲医疗体系的医疗成本(以美元表示)、效用数据和来自既往试验Meta分析的转移概率。
- FFR指导PCI较造影指导PCI增加QALYs 0.06,人均累积总费用减少1208美元,ICER为-19484美元,INB为3378美元。
- 概率敏感性分析显示结果一致,FFR指导PCI具有成本效益的迭代可能性为97%。
- 使用FLOWER-MI和FRAME-AMI试验配对Meta分析的转移概率时,FFR指导PCI在韩国、美国、欧洲医疗体系均更具成本效益,INB分别为3910、8557、2210美元。
- 概率敏感性分析中FFR指导PCI具有成本效益的迭代可能性在韩国、美国、欧洲分别为85%、82%、31%。
证据类型、等级与局限
- 证据类型:随机临床试验(FRAME-AMI)的预设成本效益分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于急性心肌梗死合并多支血管病变患者,FFR指导的非IRA病变PCI较造影指导PCI节省医疗费用并提高生活质量。
- 作者建议,在决定这类患者非IRA狭窄的治疗策略时应考虑FFR指导PCI。
指南或共识出处
- FRAME-AMI随机临床试验(ClinicalTrials.gov Identifier: NCT02715518)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Complete revascularization by non-infarct-related artery (IRA) percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is standard practice to improve patient prognosis. However, it is unclear whether a fractional flow reserve (FFR)-guided or angiography-guided treatment strategy for non-IRA PCI would be more cost-effective.
OBJECTIVE: To evaluate the cost-effectiveness of FFR-guided compared with angiography-guided PCI in patients with acute myocardial infarction and multivessel disease.
DESIGN, SETTING, AND PARTICIPANTS: In this prespecified cost-effectiveness analysis of the FRAME-AMI randomized clinical trial, patients were randomly allocated to either FFR-guided or angiography-guided PCI for non-IRA lesions between August 19, 2016, and December 24, 2020. Patients were aged 19 years or older, had ST-segment elevation myocardial infarction (STEMI) or non-STEMI and underwent successful primary or urgent PCI, and had at least 1 non-IRA lesion (diameter stenosis >50% in a major epicardial coronary artery or major side branch with a vessel diameter of ≥2.0 mm). Data analysis was performed on August 27, 2023.
INTERVENTION: Fractional flow reserve-guided vs angiography-guided PCI for non-IRA lesions.
MAIN OUTCOMES AND MEASURES: The model simulated death, myocardial infarction, and repeat revascularization. Future medical costs and benefits were discounted by 4.5% per year. The main outcomes were quality-adjusted life-years (QALYs), direct medical costs, incremental cost-effectiveness ratio (ICER), and incremental net monetary benefit (INB) of FFR-guided PCI compared with angiography-guided PCI. State-transition Markov models were applied to the Korean, US, and European health care systems using medical cost (presented in US dollars), utilities data, and transition probabilities from meta-analysis of previous trials.
RESULTS: The FRAME-AMI trial randomized 562 patients, with a mean (SD) age of 63.3 (11.4) years. Most patients were men (474 [84.3%]). Fractional flow reserve-guided PCI increased QALYs by 0.06 compared with angiography-guided PCI. The total cumulative cost per patient was estimated as $1208 less for FFR-guided compared with angiography-guided PCI. The ICER was -$19 484 and the INB was $3378, indicating that FFR-guided PCI was more cost-effective for patients with acute myocardial infarction and multivessel disease. Probabilistic sensitivity analysis showed consistent results and the likelihood iteration of cost-effectiveness in FFR-guided PCI was 97%. When transition probabilities from the pairwise meta-analysis of the FLOWER-MI and FRAME-AMI trials were used, FFR-guided PCI was more cost-effective than angiography-guided PCI in the Korean, US, and European health care systems, with an INB of $3910, $8557, and $2210, respectively. In probabilistic sensitivity analysis, the likelihood iteration of cost-effectiveness with FFR-guided PCI was 85%, 82%, and 31% for the Korean, US, and European health care systems, respectively.
CONCLUSIONS AND RELEVANCE: This cost-effectiveness analysis suggests that FFR-guided PCI for non-IRA lesions saved medical costs and increased quality of life better than angiography-guided PCI for patients with acute myocardial infarction and multivessel disease. Fractional flow reserve-guided PCI should be considered in determining the treatment strategy for non-IRA stenoses in these patients.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02715518.
参考来源
- Hong D, Lee SH, Lee J, et al. Cost-Effectiveness of Fractional Flow Reserve-Guided Treatment for Acute Myocardial Infarction and Multivessel Disease: A Prespecified Analysis of the FRAME-AMI Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38270954. doi:10.1001/jamanetworkopen.2023.52427
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。